Wird geladen...
Immunotherapeutic Mechanisms of Anti-CD20 Monoclonal Antibodies
The anti-CD20, B cell-specific mAb rituximab (RTX) has been approved for treatment of non-Hodgkin's B cell lymphoma and rheumatoid arthritis. Under conditions of high B cell burden, exhaustion of the body's effector mechanisms, e.g. NK cell-mediated killing, may lead to substantial decreas...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
2008
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2660201/ https://ncbi.nlm.nih.gov/pubmed/18585457 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.coi.2008.05.011 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|